Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025

Vinge has advised Priveq Fund VII in connection with a sustainability-linked credit facility

Priveq Fund VII has entered into a credit facility agreement with Swedbank AB (publ) which will primarily be used to finance the fund’s investment activities. The credit facility is linked to certain of Priveq’s sustainability targets, which means that the interest rate on the credit facility will be adjusted up or down based on the performance of Priveq Fund VII's portfolio companies.
February 10, 2025

Vinge advised ReCarber in financing round

Vinge has advised ReCarber AB in its SEK 60 million financing round. The investors included Luminar Ventures, Spintop Ventures and Course Corrected.
February 10, 2025